Drug Patents owned by Sebela Ireland Ltd

1. Drug name - BRISDELLE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598271 SEBELA IRELAND LTD Crystalline paroxetine methane sulfonate
May, 2025

(2 years from now)

US8946251 SEBELA IRELAND LTD Method of treating thermoregulatory dysfunction with paroxetine
Aug, 2026

(3 years from now)

US8658663 SEBELA IRELAND LTD Method of treating thermoregulatory disfunction with paroxetine
Apr, 2029

(6 years from now)

CN1256692A SEBELA IRELAND LTD 4-Phenyl-Piperidine Compound
Aug, 2008

(14 years ago)

CN1092654C SEBELA IRELAND LTD 4-Phenyl-Piperidine Compound
Aug, 2008

(14 years ago)

CN101505759A SEBELA IRELAND LTD Method Of Treating Thermoregulatory Dysfunction With Paroxetine
Aug, 2013

(9 years ago)

EP994872B1 SEBELA IRELAND LTD 4-Phenylpiperidine Compounds
Jun, 2017

(5 years ago)

EP994872A1 SEBELA IRELAND LTD 4-Phenylpiperidine Compounds
Jun, 2017

(5 years ago)

EP994872B9 SEBELA IRELAND LTD 4-Phenylpiperidine Compounds
Jun, 2017

(5 years ago)

EP2068881A2 SEBELA IRELAND LTD Method Of Treating Thermoregulatory Disfunction With Paroxetine
Jul, 2027

(4 years from now)

EP2068881A4 SEBELA IRELAND LTD Method Of Treating Thermoregulatory Disfunction With Paroxetine
Jul, 2027

(4 years from now)

EP2068881B1 SEBELA IRELAND LTD Method Of Treating Thermoregulatory Disfunction With Paroxetine
Jul, 2027

(4 years from now)

EP2719385A1 SEBELA IRELAND LTD Method Of Treating Thermoregulatory Disfunction With Paroxetine
Jul, 2027

(4 years from now)

EP2719385B1 SEBELA IRELAND LTD Method Of Treating Thermoregulatory Disfunction With Paroxetine
Jul, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393237 SEBELA IRELAND LTD Method of treating thermoregulatory dysfunction with paroxetine Aug, 2026

(3 years from now)

Drugs and Companies using PAROXETINE MESYLATE ingredient

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 7.5MG BASE CAPSULE;ORAL Prescription

2. Drug name - NAFTIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9161914 SEBELA IRELAND LTD Topical compositions and methods for making and using same Jan, 2033

(10 years from now)

US10729667 SEBELA IRELAND LTD Topical compositions and methods for making and using same Jan, 2033

(10 years from now)

US10695303 SEBELA IRELAND LTD Topical compositions and methods for making and using same Jan, 2033

(10 years from now)

US10166205 SEBELA IRELAND LTD Topical compositions and methods for making and using same Jan, 2033

(10 years from now)

US10166206 SEBELA IRELAND LTD Topical compositions and methods for making and using same Jan, 2033

(10 years from now)

US8778365 SEBELA IRELAND LTD Topical compositions and methods for making and using same Jan, 2033

(10 years from now)

Drugs and Companies using NAFTIFINE HYDROCHLORIDE ingredient

Treatment: Treatment of fungal infections

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
2% GEL;TOPICAL Prescription

3. Drug name - ONMEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8486456 SEBELA IRELAND LTD Itraconazole compositions with improved bioavailability Oct, 2028

(6 years from now)

Drugs and Companies using ITRACONAZOLE ingredient

Treatment: Onychomycosis of the toenail caused by tricophyton rubrum or trichophyton mentagrophytes, once daily use for 12 consecutive weeks

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Discontinued

4. Drug name - PEXEVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598271 SEBELA IRELAND LTD Crystalline paroxetine methane sulfonate
May, 2025

(2 years from now)

CN1256692A SEBELA IRELAND LTD 4-Phenyl-Piperidine Compound
Aug, 2008

(14 years ago)

CN1092654C SEBELA IRELAND LTD 4-Phenyl-Piperidine Compound
Aug, 2008

(14 years ago)

CN101505759A SEBELA IRELAND LTD Method Of Treating Thermoregulatory Dysfunction With Paroxetine
Aug, 2013

(9 years ago)

EP994872B1 SEBELA IRELAND LTD 4-Phenylpiperidine Compounds
Jun, 2017

(5 years ago)

EP994872A1 SEBELA IRELAND LTD 4-Phenylpiperidine Compounds
Jun, 2017

(5 years ago)

EP994872B9 SEBELA IRELAND LTD 4-Phenylpiperidine Compounds
Jun, 2017

(5 years ago)

EP2068881A2 SEBELA IRELAND LTD Method Of Treating Thermoregulatory Disfunction With Paroxetine
Jul, 2027

(4 years from now)

EP2068881A4 SEBELA IRELAND LTD Method Of Treating Thermoregulatory Disfunction With Paroxetine
Jul, 2027

(4 years from now)

EP2068881B1 SEBELA IRELAND LTD Method Of Treating Thermoregulatory Disfunction With Paroxetine
Jul, 2027

(4 years from now)

EP2719385A1 SEBELA IRELAND LTD Method Of Treating Thermoregulatory Disfunction With Paroxetine
Jul, 2027

(4 years from now)

EP2719385B1 SEBELA IRELAND LTD Method Of Treating Thermoregulatory Disfunction With Paroxetine
Jul, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE TABLET;ORAL Prescription
EQ 20MG BASE TABLET;ORAL Prescription
EQ 30MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.